Walvax BioTech Total Assets

Latest as of June 2026: CN¥10.50 Billion CNY ≈ $1.54 Billion USD

Walvax BioTech total assets. Based on the latest financial reports, Walvax BioTech (300142) holds total assets worth CN¥10.50 Billion CNY (≈ $1.54 Billion USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Walvax BioTech market cap and net worth for the company's overall valuation and market capitalisation.

Total Assets of Walvax BioTech (2007–2025)

Total assets of Walvax BioTech from 2007 to 2025. This chart illustrates how Walvax BioTech's total assets have evolved over time, based on quarterly financial data. See today's stock price for Walvax BioTech for real-time trading data and today's change.

Walvax BioTech - Asset Composition Analysis

Walvax BioTech Total Assets Breakdown (December 2025)

Walvax BioTech total assets breakdown as of December 2025. Walvax BioTech's total assets of CN¥10.50 Billion consist of 37.7% current assets and 62.3% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	11.2%
Accounts Receivable	CN¥2.29 Billion	19.0%
Inventory	CN¥574.16 Million	4.8%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥1.37 Billion	11.4%
Goodwill	CN¥33.66 Million	0.3%

Asset Composition Trend (2007–2025)

This chart illustrates how Walvax BioTech's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Walvax BioTech's working capital to assess how much short-term liquidity the company maintains relative to its equity base.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Walvax BioTech's current assets represent 37.7% of total assets in 2025, a decrease from 47.2% in 2007.
Cash Position: Cash and equivalents constituted 11.2% of total assets in 2025, down from 12.1% in 2007.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 9.0% in 2007.
Asset Diversification: The largest asset category is accounts receivable at 19.0% of total assets.

Walvax BioTech Competitors by Total Assets

Key competitors of Walvax BioTech based on total assets are shown below.

Company	Country	Total Assets
GALDERMA GROUP AG NYSE:GALDY	USA	$13.39 Billion
Takeda Pharmaceutical Company Limited F:TKDA	Germany	€15.41 Trillion
Galderma Group N SW:GALD	Switzerland	CHF12.88 Billion
Enzymatica publ AB ST:ENZY	Sweden	Skr149.24 Million
Shijiazhuang Yiling Pharmaceutical Co Ltd SHE:002603	China	CN¥13.98 Billion
Hubei Jumpcan Pharmaceutical Co Ltd SHG:600566	China	CN¥17.01 Billion
Kangmei Pharmaceutical Co Ltd SHG:600518	China	CN¥13.68 Billion
Shandong Buchang Pharmaceuticals Co Ltd SHG:603858	China	CN¥19.57 Billion

Walvax BioTech - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.07	2.82	2.76
Quick Ratio	1.77	2.56	2.43
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥2.10 Billion	CN¥4.34 Billion	CN¥4.35 Billion

Walvax BioTech - Advanced Valuation Insights

This section examines the relationship between Walvax BioTech's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	3.08
Latest Market Cap to Assets Ratio	0.21
Asset Growth Rate (YoY)	-18.0%
Total Assets	CN¥12.07 Billion
Market Capitalization	$2.55 Billion USD

Valuation Analysis

Below Book Valuation: The market values Walvax BioTech's assets below their book value (0.21x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Walvax BioTech's assets decreased by 18.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Walvax BioTech (2007–2025)

The table below shows the annual total assets of Walvax BioTech from 2007 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥12.07 Billion ≈ $1.77 Billion	-18.02%
2024-12-31	CN¥14.72 Billion ≈ $2.15 Billion	-5.55%
2023-12-31	CN¥15.59 Billion ≈ $2.28 Billion	+1.65%
2022-12-31	CN¥15.34 Billion ≈ $2.24 Billion	+12.15%
2021-12-31	CN¥13.67 Billion ≈ $2.00 Billion	+41.73%
2020-12-31	CN¥9.65 Billion ≈ $1.41 Billion	+37.48%
2019-12-31	CN¥7.02 Billion ≈ $1.03 Billion	-3.14%
2018-12-31	CN¥7.24 Billion ≈ $1.06 Billion	+23.30%
2017-12-31	CN¥5.88 Billion ≈ $859.84 Million	-7.08%
2016-12-31	CN¥6.32 Billion ≈ $925.40 Million	+1.06%
2015-12-31	CN¥6.26 Billion ≈ $915.72 Million	+4.86%
2014-12-31	CN¥5.97 Billion ≈ $873.26 Million	-2.74%
2013-12-31	CN¥6.14 Billion ≈ $897.87 Million	+37.88%
2012-12-31	CN¥4.45 Billion ≈ $651.21 Million	+47.99%
2011-12-31	CN¥3.01 Billion ≈ $440.03 Million	+0.69%
2010-12-31	CN¥2.99 Billion ≈ $437.01 Million	+673.44%
2009-12-31	CN¥386.12 Million ≈ $56.50 Million	+27.90%
2008-12-31	CN¥301.90 Million ≈ $44.18 Million	+38.79%
2007-12-31	CN¥217.52 Million ≈ $31.83 Million	--

About Walvax BioTech

SHE:300142 China Drug Manufacturers - Specialty & Generic

Market Cap

$2.55 Billion

CN¥17.42 Billion CNY

Market Cap Rank

#5185 Global

#825 in China

Share Price

CN¥10.89

Change (1 day)

-5.39%

52-Week Range

CN¥10.89 - CN¥16.10

All Time High

CN¥93.63